SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) COO Sells $1,593,900.00 in Stock

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) COO Badreddin Edris sold 30,000 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $53.13, for a total transaction of $1,593,900.00. Following the transaction, the chief operating officer now directly owns 189,712 shares of the company’s stock, valued at $10,079,398.56. The trade was a 13.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Badreddin Edris also recently made the following trade(s):

• On Tuesday, December 3rd, Badreddin Edris sold 20,000 shares of SpringWorks Therapeutics stock. The shares were sold at an average price of $41.97, for a total transaction of $839,400.00.

SpringWorks Therapeutics Stock Up 7.5 %

NASDAQ SWTX traded up $4.15 during trading hours on Wednesday, reaching $59.28. 4,270,393 shares of the company were exchanged, compared to its average volume of 2,597,517. SpringWorks Therapeutics, Inc. has a 1 year low of $28.21 and a 1 year high of $60.00. The business’s 50 day simple moving average is $38.35 and its 200-day simple moving average is $36.40. The stock has a market capitalization of $4.41 billion, a P/E ratio of -15.28 and a beta of 0.81.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.03. The firm had revenue of $49.10 million during the quarter, compared to the consensus estimate of $53.28 million. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The company’s revenue was up 4810.0% on a year-over-year basis. During the same quarter last year, the company earned ($1.27) earnings per share. As a group, sell-side analysts anticipate that SpringWorks Therapeutics, Inc. will post -3.03 earnings per share for the current year.

Hedge Funds Weigh In On SpringWorks Therapeutics

Several hedge funds have recently bought and sold shares of SWTX. Huntington National Bank raised its holdings in SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company’s stock valued at $25,000 after buying an additional 192 shares during the last quarter. AlphaQuest LLC boosted its stake in SpringWorks Therapeutics by 70.2% in the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock worth $36,000 after purchasing an additional 414 shares in the last quarter. Venturi Wealth Management LLC bought a new position in SpringWorks Therapeutics during the 4th quarter valued at about $45,000. KBC Group NV lifted its stake in SpringWorks Therapeutics by 59.1% during the 4th quarter. KBC Group NV now owns 2,634 shares of the company’s stock valued at $95,000 after acquiring an additional 978 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of SpringWorks Therapeutics by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock worth $87,000 after purchasing an additional 474 shares during the period.

Analysts Set New Price Targets

Several research firms recently commented on SWTX. HC Wainwright reiterated a “buy” rating and set a $74.00 target price on shares of SpringWorks Therapeutics in a research note on Wednesday. Evercore ISI increased their price objective on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday. Wedbush reissued an “outperform” rating and issued a $77.00 price objective on shares of SpringWorks Therapeutics in a research report on Monday. Finally, Guggenheim dropped their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $70.83.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.